FY2022 EPS Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Lifted by HC Wainwright

Milestone Pharmaceuticals Inc. (NASDAQ:MISTGet Rating) – Equities researchers at HC Wainwright lifted their FY2022 EPS estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, November 14th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.38) for the year, up from their previous estimate of ($1.41). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2022 earnings at ($0.32) EPS, Q1 2023 earnings at ($0.33) EPS, Q2 2023 earnings at ($0.34) EPS, Q3 2023 earnings at ($0.34) EPS, FY2023 earnings at ($1.30) EPS and FY2024 earnings at ($0.97) EPS.

Milestone Pharmaceuticals (NASDAQ:MISTGet Rating) last announced its earnings results on Thursday, November 10th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.07. The business had revenue of $1.50 million for the quarter.

Milestone Pharmaceuticals Trading Up 3.4 %

Shares of MIST opened at $4.53 on Wednesday. Milestone Pharmaceuticals has a 12 month low of $3.98 and a 12 month high of $9.85. The firm’s 50 day moving average is $7.06 and its 200-day moving average is $6.68. The stock has a market capitalization of $155.32 million, a PE ratio of -3.10 and a beta of 2.05.

Insider Buying and Selling

In other news, major shareholder Rtw Investments, Lp purchased 1,557,346 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Wednesday, September 7th. The shares were acquired at an average price of $8.71 per share, for a total transaction of $13,564,483.66. Following the transaction, the insider now owns 4,315,102 shares of the company’s stock, valued at approximately $37,584,538.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Rtw Investments, Lp purchased 1,557,346 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Wednesday, September 7th. The shares were acquired at an average price of $8.71 per share, for a total transaction of $13,564,483.66. Following the transaction, the insider now owns 4,315,102 shares of the company’s stock, valued at approximately $37,584,538.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert James Wills purchased 15,000 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Wednesday, October 19th. The shares were purchased at an average price of $4.93 per share, for a total transaction of $73,950.00. Following the transaction, the director now directly owns 15,000 shares in the company, valued at approximately $73,950. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 1,576,346 shares of company stock worth $13,659,474. Corporate insiders own 10.12% of the company’s stock.

Institutional Trading of Milestone Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA acquired a new stake in Milestone Pharmaceuticals in the first quarter valued at approximately $25,000. PDT Partners LLC acquired a new stake in Milestone Pharmaceuticals in the first quarter valued at approximately $65,000. JPMorgan Chase & Co. boosted its position in Milestone Pharmaceuticals by 94.7% in the first quarter. JPMorgan Chase & Co. now owns 13,580 shares of the company’s stock valued at $87,000 after buying an additional 6,606 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at approximately $107,000. Finally, Engineers Gate Manager LP acquired a new stake in Milestone Pharmaceuticals in the third quarter valued at approximately $108,000. Institutional investors and hedge funds own 69.44% of the company’s stock.

About Milestone Pharmaceuticals

(Get Rating)

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

Further Reading

Earnings History and Estimates for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.